BACKGROUND: An earlier 6-month, multicenter, open-label study in @entity1 with complex partial @entity410 found that a switch from multiple daily doses of conventional @entity2049 ( @entity2050 ) to twice-daily @entity2050 extended-release capsules( @entity2050 -ERC) was well tolerated, with maintenance of @entity410 control over the study period and significant improvements in quality of life (P < 0.001). OBJECTIVE: The goal of the present study was to assess the tolerability and effects on quality of life of twice-daily @entity2050 -ERC over the longer term in @entity1 with @entity410 disorders. METHODS: This was a multicenter, open-label assessment of the long-term(12-36 months) tolerability and quality-of-life effects of twice-daily @entity2050 -ERC given at a daily dose equivalent to the daily dose of @entity2050 taken before study en-try. The regimen could be adjusted as clinically indicated up to a daily dose of 1600 mg. @entity1 could receive up to 2 other antiepileptic drugs during the study. RESULTS: One hundred eighteen @entity1 were enrolled. In @entity1 completing>12 months of study therapy, a significant decrease in the highest mean 2-day frequency of generalized @entity410 was observed over the first 12 months (P = 0.005). The significant improvements in quality of life achieved in the earlier study were maintained during the present study. Of 37 @entity1 who were discontinued from the study, 9 met criteria mandating withdrawal from the study due to exacerbation of @entity410 . Three @entity1 were discontinued from the study for adverse events judged to be unrelated to study drug. Low incidences of @entity1910 (3.4%) and @entity1017 (0.8%) were reported. CONCLUSIONS: In this population of adults with @entity410 disorders, @entity2050 -ERC twice daily was well tolerated during 12 to 36 months of open-label treatment,with no increase in @entity410 frequency or decrease in quality of life.

Tolerability and effects on quality of life of twice-daily extended-release @entity2049 in adults with XXXX disorders: an open-label, 12- to 36-month continuation study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures', 'tonic-clonic seizures'] @entity1910 :: ('MESH:D005076', 'Disease') :: ['rash'] @entity2050 :: ('CHEBI:51097', 'Chemical') :: ['CBZ'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain'] @entity2049 :: ('MESH:D002220', 'Chemical') :: ['carbamazepine']
@entity410 :: (MESH:D012640,Disease) :: ['seizure']
